Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China.
Curr Pharm Des. 2024;30(27):2120-2128. doi: 10.2174/0113816128311861240523075218.
Primary liver cancer is the second leading cause of cancer-related death worldwide. At present, liver cancer is often in an advanced stage once diagnosed, and treatment effects are generally poor. Therefore, there is an urgent need for other powerful treatments. Macrophages are an important component of the tumor microenvironment, and macrophage polarization is crucial to tumor proliferation and differentiation. Regulatory interactions between macrophage subtypes, such as M1 and M2, lead to a number of clinical outcomes, including tumor progression and metastasis. So, it is important to study the drivers of this process. Long non-coding RNA has been widely proven to be of great value in the early diagnosis and treatment of tumors. Many studies have shown that long non-coding RNA participates in macrophage polarization through its ability to drive M1 or M2 polarization, thereby participating in the occurrence and development of liver cancer. In this article, we systematically elaborated on the long non-coding RNAs involved in the polarization of liver cancer macrophages, hoping to provide a new idea for the early diagnosis and treatment of liver cancer. Liver cancer- related studies were retrieved from PubMed. Based on our identification of lncRNA and macrophage polarization as powerful therapies for liver cancer, we analyzed research articles in the PubMed system in the last ten years on the crosstalk between lncRNA and macrophage polarization. By targeting M1/M2 macrophage polarization, lncRNA may promote or suppress liver cancer, and the references are determined primarily by the article's impact factor. Consequently, the specific mechanism of action between lncRNA and M1/M2 macrophage polarization was explored, along with the role of their crosstalk in the occurrence, proliferation, and metastasis of liver cancer. LncRNA is bidirectionally expressed in liver cancer and can target macrophage polarization to regulate tumor behavior. LncRNA mainly functions as ceRNA and can participate in the crosstalk between liver cancer cells and macrophages through extracellular vesicles. LncRNA can potentially participate in the immunotherapy of liver cancer by targeting macrophages and becoming a new biomolecular marker of liver cancer.
原发性肝癌是全球癌症相关死亡的第二大主要原因。目前，肝癌一旦诊断通常处于晚期，治疗效果普遍较差。因此，迫切需要其他强有力的治疗方法。巨噬细胞是肿瘤微环境的重要组成部分，巨噬细胞极化对肿瘤的增殖和分化至关重要。巨噬细胞亚型（如 M1 和 M2）之间的调节相互作用导致许多临床结果，包括肿瘤进展和转移。因此，研究这个过程的驱动因素很重要。长链非编码 RNA 已被广泛证明在肿瘤的早期诊断和治疗中具有巨大价值。许多研究表明，长链非编码 RNA 通过驱动 M1 或 M2 极化来参与巨噬细胞极化，从而参与肝癌的发生和发展。在本文中，我们系统地阐述了参与肝癌巨噬细胞极化的长链非编码 RNA，希望为肝癌的早期诊断和治疗提供新的思路。从 PubMed 中检索到与肝癌相关的研究。基于我们将长链非编码 RNA 和巨噬细胞极化鉴定为肝癌的有力治疗方法，我们分析了过去十年中 PubMed 系统中关于长链非编码 RNA 与巨噬细胞极化相互作用的研究文章。长链非编码 RNA 可以通过靶向 M1/M2 巨噬细胞极化来促进或抑制肝癌，主要通过文章的影响因子来确定参考文献。因此，我们探讨了长链非编码 RNA 与 M1/M2 巨噬细胞极化之间的具体作用机制，以及它们相互作用在肝癌发生、增殖和转移中的作用。长链非编码 RNA 在肝癌中呈双向表达，可以靶向巨噬细胞极化来调节肿瘤行为。长链非编码 RNA 主要作为 ceRNA 发挥作用，通过细胞外囊泡参与肝癌细胞与巨噬细胞之间的串扰。长链非编码 RNA 可以通过靶向巨噬细胞参与肝癌的免疫治疗，成为肝癌的新生物分子标志物。
Zotero 插件